GALECTIN THERAPEUTICS INC. Adjustments to Additional Paid in Capital, Warrant Issued
GALECTIN THERAPEUTICS INC. (GALT) reported Adjustments to Additional Paid in Capital, Warrant Issued of $667.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-12-31 was $454.00K.
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-09-30 was -$22.00K, a 107.14% decline year-over-year.
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-06-30 was $235.00K, a 9.62% decline year-over-year.
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for fiscal 2025 was $667.00K, a 21.07% decline from fiscal 2024.
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $845.00K, a 25.93% increase from fiscal 2023.
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $671.00K, a 25.36% decline from fiscal 2022.
- GALECTIN THERAPEUTICS INC. adjustments to additional paid in capital, warrant issued for fiscal 2022 was $899.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 0 month | Adjustments to Additional Paid in Capital, Warrant Issued | Adjustments to Additional Paid in Capital, Warrant Issued 1 month | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $432.00K derived: sum of 2 quarters · filed 2026-03-31 | $667.00K derived: sum of 3 quarters · filed 2026-08-14 | $667.00K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $213.00K derived: sum of 2 quarters · filed 2026-08-14 | $213.00K 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $235.00K 10-Q · filed 2026-08-14 | $235.00K 10-Q · filed 2026-08-14 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $308.00K derived: sum of 2 quarters · filed 2026-03-31 | $568.00K derived: sum of 3 quarters · filed 2026-03-31 | $845.00K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $308.00K 10-Q · filed 2025-11-14 | $568.00K derived: sum of 2 quarters · filed 2025-11-14 | $845.00K 10-Q · filed 2025-11-14 | $1.04M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $260.00K 10-Q · filed 2025-08-14 | $537.00K 10-Q · filed 2025-08-14 | $731.00K derived: sum of 3 quarters · filed 2025-08-14 | $731.00K derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $277.00K 10-Q · filed 2025-05-15 | $471.00K derived: sum of 2 quarters · filed 2025-05-15 | $471.00K derived: sum of 3 quarters · filed 2025-05-15 | $651.00K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $194.00K derived: sum of 2 quarters · filed 2025-03-31 | $374.00K derived: sum of 3 quarters · filed 2025-03-31 | $671.00K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $180.00K derived: sum of 2 quarters · filed 2024-11-14 | $477.00K 10-Q · filed 2024-11-14 | $638.00K derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $180.00K 10-Q · filed 2024-08-13 | $477.00K 10-Q · filed 2024-08-13 | $638.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.38M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $297.00K 10-Q · filed 2024-05-15 | $458.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.20M derived: sum of 3 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $899.00K derived: sum of 2 quarters · filed 2024-03-29 | $899.00K 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $738.00K 10-Q · filed 2023-11-13 | $738.00K 10-Q · filed 2023-11-13 | |||||
| 2017-12-31 | $696.00K 10-K · filed 2019-03-06 | ||||||
| 2013-12-31 | -$8.76M 10-K · filed 2015-03-18 | ||||||
| 2008-07-02 | $20.00K 10-K · filed 2014-03-21 | $20.00K 10-K · filed 2013-03-29 | |||||
| 2008-06-30 | $2.16M 10-K · filed 2014-03-21 | ||||||
| 2008-05-21 | $502.00K 10-K · filed 2014-03-21 | $502.00K 10-K · filed 2018-03-29 | $502.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |